Merck’s Phase 3 Study Shows Success in Breast Cancer Treatment
Merck announced that the Phase 3 KEYNOTE-522 study of Keytruda (anti-PD-1 therapy) met its overall survival endpoint in high-risk early-stage triple-negative breast cancer (TNBC). In combination with chemotherapy as a pre-operative treatment and subsequent monotherapy after surgery, Keytruda showed significant improvement compared to chemotherapy alone. No new safety concerns were identified. This is the first time an immunotherapy-based treatment has shown a survival benefit in TNBC patients.
